Safety of Gam-COVID-Vac (Sputnik V) Combined Vector Vaccine in Patients With Immunoinflammatory Rheumatic Diseases: Preliminary Data

Background. Patients with autoimmune and inflammatory rheumatic diseases (AIRDs) are at high risk of developing COVID-19. Vaccination is an effective method of preventing this disease, which may be unsafe for patients with AIRDs.
The aim of the study is to assess the safety of Gam-COVID-Vac in patients with IVRD in real clinical practice.
Material and methods. A cross-sectional study was carried out. The main group consisted of patients with AIRDs, the control group consisted of individuals without AIRDs. All participants were interviewed by the research physician using a unified questionnaire, additional information was obtained from medical records.
Results. The study included 222 patients with AIRDs (119 with rheumatoid arthritis, 36 with ankylosing spondylitis, 17 with psoriatic arthritis, 17 with Sjögren's disease, 10 with undifferentiated spondyloarthritis, 8 with systemic lupus erythematosus, 4 with metabolic arthritis, 3 with systemic scleroderma, 3 with systemic vasculitis, 2 with polymyalgia rheumatica, 2 with undifferentiated systemic connective tissue disease, 1 with adult Still's disease) and 111 patients without AIRDs. The number of patients with AIRDs who had a combination of local and systemic adverse events (AE) on the introduction of the first component of the vaccine was significantly less than in the control group (22.1 and 44.1%, respectively, P<0.001). Similar differences were also noted after the introduction of the second component (14.0 and 29.7%, respectively, P<0.001). AEs such as pain at the injection site without restriction of movement, weakness, fever, arthralgia/myalgia, headache, and chills were significantly more common in the control group after the introduction of the first component of the vaccine. After complete immunization, AEs were absent in 35.6% of patients with AIRDs and in 21.6% of control group patients (P=0.01). Exacerbations of AIRDs and new autoimmune phenomena were not registered in any cases.
Conclusions. According to preliminary data, immunization of patients with AIRDs with the Gam-COVID-Vac combined vector vaccine appears to be quite safe.

1. Belov B.S., Muravyova N.V., Tarasova G.M. COVID-19: Rheumatological Aspects. Effective Pharmacotherapy. 2020; 16 (16): 18–25. https://doi.org/10.33978/2307-3586-2020-16-16-18-25 (in Russian)

2. Akiyama S., Hamdeh S., Micic D., Sakuraba A. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis. 2020 Oct; annrheumdis-2020-218946. doi:10.1136/annrheumdis-2020-218946. Online ahead of print.

3. Conway R., Grimshaw A.A., Konig M.F., Putman M., Duarte-García A., Tsenget L.Y. et al. SARS-CoV-2 infection and COVID-19 outcomes in rheumatic disease: a systematic literature review and meta-analysis. Arthritis Rheumatol. 2022; 74 (5): 766–775. doi:10.1002/art.42030.

4. Belov B.S., Lila A.M., Nasonov E.L. Vaccination against SARS-CoV-2 in rheumatic diseases: Safety issues. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2022; 60 (1): 21–31. https://doi.org/10.47360/1995-4484-2022-21-31 (in Russian)

5. Logunov D.Y., Dolzhikova I.V., Shcheblyakov D.V., Tukhvatulin A.I., Zubkova O.V., Dzharullaeva A.S. et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021; 397 (10275): 671–681. doi:10.1016/S0140-6736(21)00234-8.

6. Bulanov N., Novikov P., Gulyaev S., Smitienko I.O., Meshkov A.D., Borodin O.O. et al. Tolerability and safety of Gam-COVID-Vac (Sputnik V) vaccine in adult patients with autoimmune rheumatic diseases. Klinicheskaya Farmakologiya i Terapiya. 2021; 30 (4): 23–28. https://doi.org/10.32756/0869-5490-2021-4-23-28. (in Russian)

7. Kulikov A.N., Muravyeva N.V., Belov B.S. Safety of COVID-19 vaccines in patients with immunoinflammatory rheumatic diseases (preliminary data). Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2022; 16 (1): 26–31. https://doi.org/10.14412/1996-7012-2022-1-26-31. (in Russian)

8. Braun-Moscovici Y., Kaplan M., Braun M., Markovits D., Giryes S., Toledano K. et al. Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2. Ann Rheum Dis. 2021; 80 (10): 1317–1321. doi:10.1136/annrheumdis-2021-220503.

9. Furer V., Eviatar T., Zisman D., Peleg H., Paran D., Levartovsky D. et al. Immunogenicity and safety of the BNT162B2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and general population: a multicenter study. Ann Rheum Dis. 2021; 80 (10): 1330–1338. doi:10.1136/annrheumdis-2021-220647.

10. Sattui S.E., Liew J.W., Kennedy K., Sirotich E., Putman M., Moni T.T. et al. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open. 2021; 7 (3): e001814. doi:10.1136/rmdopen-2021-001814.

11. Fragoulis G.E., Bournia V.K., Mavrea E., Evangelatos G., Fragiadaki K., Karamanakos A. et al. COVID-19 vaccine safety and nocebo-prone associated hesitancy in patients with systemic rheumatic diseases: A crosssectional study. Rheumatol Int. 2021; 42 (1): 31–39. doi:10.1007/s00296-021-05039-3.

12. Cherian S., Paul A., Ahmed S., Alias B., Manoj M., Santhosh A.K. et al. Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: A post-vaccination crosssectional survey. Rheumatol Int. 2021; 41 (8): 1441–1445. doi:10.1007/s00296-021-04917-0.

13. Barbhaiya M., Levine J.M., Bykerk V.P., Jannat-Khah D., Mandl L.A. Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City. Ann Rheum Dis. 2021; 80 (10): 1352–1354. doi:10.1136/annrheumdis-2021-220732.

14. Izmirly P.M., Kim M.Y., Samanovic M., Fernandez-Ruiz R., Ohana S., Deonaraine K.D. et al. Evaluation of immune response and disease status in systemic lupus erythematosus patients following SARS-CoV-2 vaccination. Arthritis Rheumatol. 2021; 74 (2): 284–294. doi:10.1002/art.41937.

15. Nasonov E.L., Lila A.M., Mazurov V.I., Belov B.S., Karateev A.E., Dubinina T.V. et al. Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2021; 59 (3): 239–54. https://doi.org/10.47360/1995-4484-2021-239-254. (in Russian)